Drug Identification System

PillID

← Drug Encyclopedia 🌙

Uses & FDA Indications

Aripiprazole holds a broad array of FDA approvals spanning multiple psychiatric conditions in adults and children. It is one of the few antipsychotics approved as young as age 6.

FDA-Approved Uses

• Schizophrenia — adults and adolescents (13 and older)
• Bipolar I disorder, manic and mixed episodes — adults and pediatric patients (10 and older), as monotherapy or adjunct
• Major depressive disorder — adjunctive therapy in adults
• Irritability associated with autistic disorder — children and adolescents (6–17)
• Tourette's disorder — children and adolescents (6–18)
• Agitation associated with schizophrenia or bipolar mania — acute intramuscular injection

Off-Label Uses

• Adjunct for anxiety disorders and PTSD
• Borderline personality disorder
• Augmentation in treatment-resistant OCD

How It Works

Aripiprazole's mechanism is distinct among antipsychotics. Rather than simply blocking dopamine receptors, it acts as a partial agonist at D2 and D3 receptors — meaning it activates these receptors at a lower level than dopamine itself. In areas of the brain with excessive dopamine activity (such as the mesolimbic pathway, implicated in psychosis), aripiprazole competes with dopamine and reduces net receptor stimulation. In areas with insufficient dopamine (such as the prefrontal cortex), it provides mild stimulation, potentially improving negative and cognitive symptoms.

Aripiprazole also acts as a partial agonist at serotonin 5-HT1A receptors (which may contribute to anxiolytic and antidepressant effects) and as an antagonist at 5-HT2A receptors (helping modulate mood and reduce extrapyramidal effects). It has minimal affinity for histamine H1 and muscarinic receptors, explaining its low sedation and anticholinergic side-effect burden compared to other antipsychotics.

Side Effects

Common

• Akathisia (restlessness, inner urge to move) — more common than with many other atypicals
• Nausea, vomiting, and constipation
• Headache and insomnia
• Fatigue and somnolence (less than most antipsychotics)
• Anxiety and agitation
• Weight gain (less pronounced than olanzapine or quetiapine)
• Tremor and extrapyramidal symptoms at higher exposures

Serious

• Tardive dyskinesia — involuntary movements with prolonged use; risk is lower than with typical antipsychotics
• Neuroleptic malignant syndrome (NMS) — rare but potentially fatal
• Impulse control disorders — compulsive gambling, hypersexuality, binge eating; class-level concern for partial dopamine agonists
• Orthostatic hypotension — particularly with injectable formulations
• Hyperglycemia and diabetes mellitus — class effect; monitor metabolic parameters
• Suicidal ideation — increased risk in younger patients with psychiatric conditions

Drug Interactions

Drug / Class	Interaction	Clinical Significance
CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion)	Significantly increase aripiprazole plasma levels; CYP2D6 is a major metabolic pathway	High — dose reduction of aripiprazole typically needed
CYP3A4 inhibitors (ketoconazole, clarithromycin)	Increase aripiprazole concentrations via inhibition of secondary metabolic pathway	Moderate–High — monitor for toxicity; dose adjustment may be required
CYP3A4 inducers (carbamazepine, rifampin)	Reduce aripiprazole plasma levels substantially, potentially reducing efficacy	High — consider dose increase if inducers cannot be avoided
CNS depressants (benzodiazepines, opioids, alcohol)	Additive sedation and cardiorespiratory depression; case reports of serious events with IM aripiprazole + IM lorazepam	High — avoid IM aripiprazole with IM lorazepam; caution with oral combinations
Antihypertensives	Alpha-1 blockade enhances hypotensive effect	Moderate — monitor blood pressure
Levodopa / dopamine agonists	Partial D2 agonism may antagonize therapeutic effect in Parkinson's disease	Moderate — use with caution; consider clozapine if antipsychotic is required for Parkinson's psychosis
Metoclopramide	Additive dopamine antagonism increases extrapyramidal and akathisia risk	Moderate — avoid concurrent use when possible

Warnings & Contraindications

Key Precautions

• Impulse control: Patients should be monitored for new or worsening compulsive behaviors including gambling and hypersexuality; discontinuation may be required
• Metabolic effects: Monitor weight, fasting glucose, and lipids at baseline and periodically; class effect exists despite better relative profile
• Akathisia: Can be distressing and mistaken for worsening agitation; may require dose reduction or adjunctive beta-blocker
• CYP2D6 poor metabolizers: Patients who are CYP2D6 poor metabolizers may have significantly higher drug exposure; adjust accordingly
• Abilify MyCite: The sensor-embedded tablet version tracks ingestion; privacy and consent considerations apply
• Pregnancy: Use only when clearly needed; neonates may exhibit extrapyramidal symptoms or withdrawal after third-trimester exposure

Frequently Asked Questions

How is aripiprazole different from other antipsychotics?

Most antipsychotics work by blocking dopamine D2 receptors. Aripiprazole instead partially activates these receptors, providing a stabilizing effect on dopamine tone. This mechanism results in lower rates of weight gain, sedation, and prolactin elevation compared to full D2 antagonists like haloperidol or olanzapine. However, akathisia (restlessness) may be more prominent.

Does aripiprazole cause weight gain?

Weight gain can occur with aripiprazole but is generally considered less than with olanzapine or quetiapine. Its low affinity for histamine H1 and serotonin 5-HT2C receptors — the main drivers of antipsychotic-related weight gain — accounts for this advantage. Still, metabolic monitoring is recommended for all patients on any antipsychotic.

What is akathisia and why does aripiprazole cause it?

Akathisia is a feeling of inner restlessness and an irresistible urge to keep moving. It is thought to arise from dopamine system modulation. Because aripiprazole is a partial agonist rather than a full blocker, it can cause akathisia more readily than pure antagonists in some patients, particularly at the start of therapy. Management options include dose reduction, switching agents, or adding a low-dose beta-blocker such as propranolol.

Can aripiprazole be given as an injection?

Yes. Long-acting injectable (LAI) formulations are available: Abilify Maintena is injected monthly, and Aristada is available in several injection intervals. These formulations are used for maintenance treatment in schizophrenia or bipolar I disorder when adherence to daily oral medication is a concern. A separate short-acting intramuscular formulation is used for acute agitation.

→ Antipsychotic Side Effects Guide